Moderna
-
FDA Approves Moderna’s mRNA-Based Flu Vaccine for Older Adults
The FDA has approved mFlusiva, Moderna’s mRNA-based flu vaccine for adults 50 and older, offering a new tool to combat seasonal influenza.
-
FDA Approves Moderna’s mRNA Flu Vaccine mFlusiva for Adults 50 and Older
The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 and older, marking a major shift in vaccine technology.
-
FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration has reversed its initial refusal, agreeing to review Moderna’s mRNA flu vaccine application for the 2026/2027 flu season.
-
Dow Jones Dips 400 Points as Inflation, JPMorgan Earnings, and Trump’s Policies Sway Markets
Major U.S. stock indexes, including the Dow Jones Industrial Average, closed lower after investors assessed December’s CPI data, JPMorgan’s earnings, and President Trump’s proposals on credit card interest rates and tariffs.